• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Pelthos Therapeutics Inc.

    5/22/26 12:46:08 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PTHS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001433316
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Pelthos Therapeutics Inc.
    SEC File Number
    001-41964
    Address of Issuer
    4020 STIRRUP CREEK DRIVE
    SUITE 110
    DURHAM
    NORTH CAROLINA
    27703
    Phone
    919-908-2422
    Name of Person for Whose Account the Securities are To Be Sold
    Francis Knuettel II
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    245 Summer Street
    Boston � MA � 02110
    172046629.20347564505/22/2026
    ASE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/13/2024MarketMarketCheckbox not checked35009/13/2024Cash
    Common09/12/2024MarketMarketCheckbox not checked17009/12/2024Cash
    Common09/11/2024MarketMarketCheckbox not checked55009/11/2024Cash
    Common09/10/2024MarketMarketCheckbox not checked65009/10/2024Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Shares sold out of account: L Knuettel, F Knuettell II TTEE Lara Knuettel Revocable Trust
    Date of Notice
    05/22/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Christian Nasser as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Francis Knuettel II

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $PTHS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTHS

    DatePrice TargetRatingAnalyst
    4/1/2026$50.00Overweight
    Cantor Fitzgerald
    2/27/2026$48.00Overweight
    Piper Sandler
    12/3/2025$50.00Buy
    Lake Street
    12/3/2025$60.00Buy
    H.C. Wainwright
    11/25/2025$57.00Buy
    Roth Capital
    9/2/2025$50.00Outperform
    Oppenheimer
    More analyst ratings

    $PTHS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO, Treas & Secty Francis Knuettel Ii returned 13,947 shares to the company and sold $40,265 worth of shares (1,500 units at $26.84), decreasing direct ownership by 42% to 19,525 units (SEC Form 4)

    4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

    5/26/26 7:17:24 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Friedberg Ezra M covered exercise/tax liability with 144 shares, decreasing direct ownership by 0.18% to 81,883 units (SEC Form 4) (withholding obligation)

    4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

    5/18/26 6:11:12 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Gay John M.

    3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

    4/20/26 5:00:41 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTHS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

    DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies representative. About Pelthos Therapeutics Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease prod

    5/28/26 5:00:00 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pelthos Therapeutics Announces First Quarter 2026 Financial Results

     ZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units dispensed Management will host a conference call today, May 14, 2026, at 8:30 a.m. ET DURHAM, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos," "we" or the "Company"), today announced its financial results for the first quarter ended March 31,

    5/14/26 7:00:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026

    DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern time. Details for the conference call can be found below: Date:   Thursday, May 14, 2026Time:     8:30 a.m. Eastern TimeToll Free:  1-877-451-6152International:  1-201-389-0879Conf. ID: 13760399 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1761761&tp_key=d31924f2e0 About Peltho

    5/1/26 8:30:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTHS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Pelthos Therapeutics Inc. with a new price target

    Cantor Fitzgerald initiated coverage of Pelthos Therapeutics Inc. with a rating of Overweight and set a new price target of $50.00

    4/1/26 8:49:08 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Pelthos Therapeutics Inc. with a new price target

    Piper Sandler initiated coverage of Pelthos Therapeutics Inc. with a rating of Overweight and set a new price target of $48.00

    2/27/26 8:31:30 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lake Street initiated coverage on Pelthos Therapeutics Inc. with a new price target

    Lake Street initiated coverage of Pelthos Therapeutics Inc. with a rating of Buy and set a new price target of $50.00

    12/3/25 8:16:35 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTHS
    SEC Filings

    View All

    Pelthos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)

    5/28/26 5:01:24 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Pelthos Therapeutics Inc.

    144 - Pelthos Therapeutics Inc. (0001919246) (Subject)

    5/22/26 12:46:08 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pelthos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Leadership Update, Financial Statements and Exhibits

    8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)

    5/21/26 5:00:16 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTHS
    Leadership Updates

    Live Leadership Updates

    View All

    Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn

    DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it has named veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Mr. Einhorn will serve on the Board of Directors until Pelthos' 2026 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation or removal. Also, effective immediately, Mr. Einhorn will also serve on the Audit Committee and the Compensation Committee of the Pelthos Board of Directors. Mr. Einhorn brings ext

    12/23/25 5:57:12 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum

    The Moms Against Molluscum movement aims to empower families impacted by molluscum to share their personal stories and encourage others to join the conversationMolluscum is a highly contagious skin infection affecting 16.7 million Americans, mainly childrenMomsAgainstMolluscum.com will offer new resources to support moms, parents, and other caregivers of molluscum patients DURHAM, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced the launch of Moms Against Molluscum, a movement to unite mothers, parents, and other careg

    10/9/25 8:00:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

    Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and olderCompletes build-out of essential management operational infrastructure and hires 50 territory sales managers DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high unmet patient nee

    8/18/25 8:00:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTHS
    Financials

    Live finance-specific insights

    View All

    Pelthos Therapeutics Announces First Quarter 2026 Financial Results

     ZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units dispensed Management will host a conference call today, May 14, 2026, at 8:30 a.m. ET DURHAM, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos," "we" or the "Company"), today announced its financial results for the first quarter ended March 31,

    5/14/26 7:00:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026

    DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern time. Details for the conference call can be found below: Date:   Thursday, May 14, 2026Time:     8:30 a.m. Eastern TimeToll Free:  1-877-451-6152International:  1-201-389-0879Conf. ID: 13760399 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1761761&tp_key=d31924f2e0 About Peltho

    5/1/26 8:30:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

    ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025. 8,948 ZELSUVMI units prescribed by 2,712 unique prescribers for fiscal year 2025, with a 129% quarter over quarter increase in units dispensed, rising from 2,716 units in the third quarter of 2025 to 6,232 units in the fourth quarter of 2025. Management will host a conference call today at 8:00 a.m. EDT DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmace

    3/19/26 6:30:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care